Market Research Report
Graft Versus Host Disease (GVHD): Competitive Landscape to 2026
|Graft Versus Host Disease (GVHD): Competitive Landscape to 2026|
Published: June 30, 2018
Content info: 51 Pages
Delivery time: 1-2 business days
Hematopoietic stem cell transplantation (HSCT) is the transplantation of autologous or allogeneic stem cells, and is used for the treatment of patients with hematologic disorders, which vary from malignant diseases to genetic anemias. Despite matching or minimally mismatching donors, there are minor histocompatibility antigens that might not match (or for other reasons), triggering the donor's immune system to attack the recipient, causing the inflammatory disease unique to allogeneic HSCT known as graft versus host disease (GVHD).
This report provides an assessment of the pipeline, clinical, and commercial landscape of GVHD. Overall, GlobalData expects new drug approvals to drive GVHD market growth over the next decade (2016-2026).
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -